Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

Delayed Quote. Delayed  - 09/26 10:01:00 pm
89.92 USD   -0.75%
09/25 PHARMACY SHUTDO : Independent businesses being swallowed up by falli..
09/22 DAILY DIVIDEND : Lmt, idcc, safm, cvs, len
09/22 CVS HEALTH CORP : Announces Quarterly Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 02:59pm CEST

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Same-store sales growth exceeds monthly data posted by Walgreen, Rite Aid

(Updates with CEO interview comments, additional background and the latest stock quote, beginning in the first paragraph.)

 
   By John Kell 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Shares were up 1.5% to $52.50 in premarket trading.

--Tess Stynes contributed to this article

Write to John Kell at john.kell@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
09/25 PHARMACY SHUTDOWNS : Independent businesses being swallowed up by falling reimbu..
09/22 DAILY DIVIDEND REPORT : Lmt, idcc, safm, cvs, len
09/22 CVS HEALTH CORPORATION : Announces Quarterly Dividend
09/22 CVS HEALTH : The First Tobacco-Free Generation Is Within Reach
09/22 CVS HEALTH : to offer curbside pickup in Chicago area
09/19 CVS HEALTH : Expands Youth Drug Abuse Prevention Efforts for the 2016-2017 Schoo..
09/15 CVS HEALTH : Increasing Access to Health Care with Annual Project Health Campaig..
09/15 CVS HEALTH : 's ScriptSync® Service Marks One Year Anniversary
09/15 CVS HEALTH : EDITORIAL CVS settlement is positive step in addiction fight
09/14 CVS HEALTH : Bringing Health Screenings to Underserved Communities
More news
Sector news : Drug Retailers - NEC
09/23DJRITE AID : Business Watch -- WSJ
09/22DJRITE AID : Same-Store Sales Fall Amid Generics Pressure
09/15 MCKESSON : German antitrust watchdog raids drugs distributors
09/14DJGoogle Acquisition Apigee's Revenue Climbs
09/14DJGoogle Acquisition Apigee's Revenue Climbs
More sector news : Drug Retailers - NEC
News from SeekingAlpha
09/25 PORTFOLIO PURCHASES : Adding 3 Companies With More Than 15% Upside To Our Divide..
09/23 Examining The Core Value Of REITs
09/22 Where Did All That EpiPen Money Go?
09/22 CVS Health declares $0.425 dividend
09/22 Amazon Threatens The Photo Printing Services Of Shutterfly, CVS, Walgreens, W..
Advertisement
Financials ($)
Sales 2016 179 864 M
EBIT 2016 10 786 M
Net income 2016 5 715 M
Debt 2016 24 998 M
Yield 2016 1,80%
P/E ratio 2016 17,50
P/E ratio 2017 14,55
EV / Sales 2016 0,68x
EV / Sales 2017 0,62x
Capitalization 96 599 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 111 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-7.33%96 599
WALGREENS BOOTS ALLIAN..-3.65%88 804
EXPRESS SCRIPTS HOLDIN..-18.38%44 960
MCKESSON CORPORATION-15.29%37 710
CARDINAL HEALTH INC-13.01%24 848
AMERISOURCEBERGEN CORP..-19.65%19 823
More Results